ZEJULA 100 mg, hard capsule 56 capsules
Active ingredients: Niraparib, Niraparib tosylate monohydrate
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule56 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ZEJULA 100 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 56 plaquette(s) thermoformée(s) (ACLAR RX) polytrifluorochloroéthylène PVC aluminium de 1 gélule(s)
- Marketing authorisation holder
- GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 13 Jun 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67707919CIP73013085CIP133400930130858Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TOSYLATE DE NIRAPARIB MONOHYDRATÉgélule | — | SA |
| NIRAPARIBgélule | 100 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.